Blood-Based Biomarkers in Sarcoma: A ‘Multi-Omics’ Approach

Overview

Información sobre este estudio

The purpose of this research is to determine whether circulating tumor DNA, RNA or proteins can be detected in the blood of patients with sarcoma. We are also interested in learning if these levels change over time while receiving chemotherapy. Patients with advanced sarcoma who will receive chemotherapy will be asked to participate. Study participation involves blood-draws of approximately 4 tablespoons of blood at each of 4 separate time-points as well as access to archived tumor tissue, or fresh tumor tissue at the time of clinically indicated biopsy or surgery.  We hypothesize that circulating tumor DNA, RNA and/or proteins will be detectable in blood of sarcoma patients, and change in measured values over time will correlate with disease response or progression on therapy.

Pediatric patients weighing at least 10 kg will be considered for enrollment. For pediatric participants, 1.5 tablespoons of blood at each of 4 separate time-points will be collected. All blood collection will coincide with clinical lab draws. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Adult and pediatric patients will be considered eligible for accrual.
  • Pediatric patients (Age < 18 years) must weigh ≥ 10 kg for consideration.
  • Diagnosis of previously untreated or progressive sarcoma who will receive systemic chemotherapy.
  • Willing and able to provide written informed consent and age appropriate assent for minors.
  • Planned clinical biopsy/surgery or available archived tumor tissue.

Exclusion Criteria: 

  • Pediatric sarcoma patients weighing < 10 kg.
  • Unable/unwilling to provide written informed consent.

Eligibility last updated 1/13/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Brittany Siontis, M.D.

Cerrado para la inscripción

Contact information:

Brittany Siontis M.D.

(507) 293-0585

Siontis.Brittany@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20502720

Mayo Clinic Footer